Fanconi anemia with biallelic FANCD1/BRCA2 mutations - Case report of a family with three affected children.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Medical Genetics

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejmg.2015.11.013PMID 26657402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preemptive Bone Marrow Transplantation for FANCD1/BRCA2.

  2015cited by this paper
• Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.

  2015cited by this paper
• Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup

  2015cited by this paper
• An update on PARP inhibitors for the treatment of cancer

  2015cited by this paper
• Fanconi anemia and the development of leukemia.

  2014cited by this paper
• Flow diagnostics essential code: A simple and brief format for the summary of leukemia phenotyping

  2014cited by this paper
• Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling

  2013cited by this paper
• Gain of 1q is a marker of poor prognosis in Wilms' tumors

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Targeting PARP in Cancer Treatment

  2013cited by this paper
• Gene Therapy for Fanconi Anemia: One Step Closer to the Clinic

  2012cited by this paper
• The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations

  2012cited by this paper
• Molecular pathogenesis and clinical management of Fanconi anemia.

  2012cited by this paper
• VACTERL-H Association and Fanconi Anemia

  2012cited by this paper
• Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

  2011cited by this paper
• BRCA in breast cancer: ESMO clinical recommendations.

  2009cited by this paper
• Fanconi anemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor

  2009cited by this paper
• Fanconi Anemia: Fanconi anemia, breast and embryonal cancer risk revisited

  2007cited by this paper
• A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

  2007cited by this paper
• Fanconi anaemia genes and susceptibility to cancer

  2006cited by this paper
• Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2

  2006cited by this paper
• Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

  2005cited by this paper
• Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour

  2005cited by this paper
• Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.

  2004cited by this paper
• Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.

  2004cited by this paper
• Biallelic Inactivation of BRCA2 in Fanconi Anemia

  2002cited by this paper

• Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing

  2024cites this paper
• Longitudinal clinical manifestations of Fanconi anemia: A systematized review.

  2024cites this paper
• Complex Interplay between DNA Damage and Autophagy in Disease and Therapy

  2024cites this paper
• Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies.

  2024cites this paper
• Pathological consequences of DNA damage in the kidney

  2023cites this paper
• Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets

  2020cites this paper
• Compound Heterozygous Variants in Pediatric Cancers: A Systematic Review

  2020cites this paper
• Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia

  2019cites this paper
• childhood T-cell

  2019cites this paper
• Risks of Solid Tumors in Heterozygous Carriers of Recessive Syndromes

  2019influential citation
• Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting ETV6.

  2019cites this paper
• Fanconi anemia in twins with neutropenia: A case report.

  2018cites this paper
• Essential Role of BRCA2 in Ovarian Development and Function

  2018cites this paper
• Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology

  2017cites this paper
• Fanconi anemia: correlating central nervous system malformations and genetic complementation groups

  2017cites this paper